GeneFluidics

GeneFluidics is a molecular diagnostics company that develops high-sensitivity testing platforms for rapid pathogen identification and antimicrobial susceptibility testing. The company's proprietary technology utilizes electrochemical sensor arrays and microfluidics to enable the direct detection of target molecules, such as ribosomal RNA, without the need for PCR amplification. Their primary focus is on point-of-care applications for infectious diseases, including urinary tract infections and sepsis, where rapid results are critical for effective treatment. By streamlining the diagnostic workflow, GeneFluidics aims to improve patient outcomes and support global antibiotic stewardship efforts. The company is headquartered in Irwindale, California, and has been supported by extensive funding from the National Institutes of Health.